A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)

Phase 2CompletedNCT00901979

Novartis Pharmaceuticals693 enrolled

Overview

This study will assess the effect of LCQ when added to metformin.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

693

Conditions

Type 2 Diabetes Mellitus

Interventions

LCQ908ADRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HbA1c from 7.0-10.0%, Stable Metformin dose Exclusion Criteria: * CHF Class III-IV, Liver disease Other protocol-defined inclusion/exclusion criteria may apply

Locations (67)

Outcomes

Primary Outcomes

Effect of LCQ on measures of glucose control

Time frame: 12 weeks

Secondary Outcomes

Changes in body weight and related measures

Time frame: 12 weeks

Insulin sensitivity

Time frame: 12 weeks

Safety and tolerability

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Clinical Research Advantage

Mesa, Arizona, United States

Mesa Family Medical Center/Clinical Research Advantage

Mesa, Arizona, United States

Woodland International Reserach Group, LLC

Little Rock, Arkansas, United States

Associated Pharmaceutical Research

Buena Park, California, United States

John Muir Clinical Research

Concord, California, United States

*Private Practice*

Pasadena, California, United States

Apex Research of Riverside

Riverside, California, United States

California Research Foundation

San Diego, California, United States

CNRI-San Diego, LLC

San Diego, California, United States

Orange County Research Center

Tustin, California, United States

...and 57 more locations